TRACON Pharmaceuticals (TCON) Is At $2.05 Formed Wedge; Shiftpixy (PIXY) Shorts Lowered By 22.94%

August 29, 2017 - By Migdalia James

Shiftpixy Incorporated (NASDAQ:PIXY) had a decrease of 22.94% in short interest. PIXY’s SI was 43,000 shares in August as released by FINRA. Its down 22.94% from 55,800 shares previously. With 440,200 avg volume, 0 days are for Shiftpixy Incorporated (NASDAQ:PIXY)’s short sellers to cover PIXY’s short positions. The stock increased 1.01% or $0.04 during the last trading session, reaching $4. About shares traded. ShiftPixy Inc (NASDAQ:PIXY) has 0.00% since August 29, 2016 and is . It has underperformed by 16.70% the S&P500.

TRACON Pharmaceuticals Inc (TCON) formed wedge down with $1.91 target or 7.00% below today’s $2.05 share price. TRACON Pharmaceuticals Inc (TCON) has $34.14 million valuation. The stock decreased 6.82% or $0.15 on August 28, reaching $2.05. About shares traded. TRACON Pharmaceuticals Inc (NASDAQ:TCON) has declined 52.06% since August 29, 2016 and is downtrending. It has underperformed by 68.76% the S&P500.

Shiftpixy, Inc. is a provider of employment law compliance solutions for employers and workers in an environment in which shift or other part-time/temporary positions are performed. The company has market cap of $114.17 million. The Firm offers ShiftPixy Employer Solution and ShiftPixy Shifter Solution. It currently has negative earnings. The Firm absorbs the employer’s shifters as its employees and makes these employees available to the former employer to work the same jobs, as employees of ShiftPixy.

Among 4 analysts covering Tracon Pharmaceuticals Inc (NASDAQ:TCON), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Tracon Pharmaceuticals Inc had 4 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Buy” rating by Roth Capital on Wednesday, July 29. Jefferies initiated the shares of TCON in report on Wednesday, December 21 with “Buy” rating. The rating was upgraded by Zacks on Friday, September 4 to “Hold”. TH Capital initiated TRACON Pharmaceuticals Inc (NASDAQ:TCON) rating on Wednesday, July 29. TH Capital has “Buy” rating and $18 target.